| Literature DB >> 35845591 |
Yuhui Duan1, Hongyu Dai1, Yongcheng An2, Long Cheng1, Lu Shi1, Yinglan Lv1, Huimin Li1, Chen Wang2, Changhao He1, Huilin Zhang1, Yan Huang2, Wanxin Fu2, Yanyan Meng3, Baosheng Zhao3.
Abstract
The incidence of liver-related complications in type 2 diabetes mellitus (T2DM) is rapidly increasing, which affects the physical and mental health of T2DM patients. Mulberry leaf flavonoids (MLF) were confirmed to have certain effects on lowering blood glucose and anti-inflammation. In this study, the high-fat diet (HFD) + STZ method was used to establish T2DM rat model and the MLF was administered by gavage for eight weeks. During the experiment, body weight and blood glucose level were measured at different time points. The pathological changes of rat liver were observed by H&E staining. The serum glucolipid metabolic indicators of serum, fasting insulin (FINS), and inflammatory factors levels were detected by ELISA. The expression levels of toll-like receptor 4 (TLR4), TNF receptor-associated factor 6 (TRAF6), myeloid differentiation factor 88 (MyD88), inhibitor of NF-κB alpha (IκΒα), p-IκΒα, and nuclear factor kappa-B (NF-κB)/p65 protein in liver tissue were measured by Western Blot. After 8 weeks' MLF treatment, the blood glucose of rats showed a downward trend; glycolipid metabolism level and insulin resistance were improved, which suggested that MLF could improve the disorder of glucose and lipid metabolism. The pathological damage and inflammation of the liver in T2DM rats were significantly improved, the levels of related serum inflammatory factors were reduced, and the expression of liver tissue-related proteins was downregulated. Our results indicated that MLF could reduce blood glucose and inhibit the development of liver inflammation. The mechanisms may be associated with the activation of TLR4/MyD88/NF-κB signal pathway to reduce the levels of inflammatory factors in serum.Entities:
Year: 2022 PMID: 35845591 PMCID: PMC9279020 DOI: 10.1155/2022/3354062
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1(a) Effects of MLF treatment on body weight (g ). (b) Effects of MLF treatment on fasting blood glucose (g/g, ). Data are presented as mean ± SD. #p < 0.05, ##p < 0.01 versus control group; p < 0.05, p < 0.01 versus T2DM group.
Figure 2(a) The effect of MLF on blood glucose in rats (mmol/l, ). (b) The effect of MLF on OGTT in rats (mmol/l, ). (c) AUC of OGTT value ().
Figure 3(a) Effects of MLF on INS level in rats (mU/L, ). (b) Effects of MLF on insulin resistance index of rats ().
Figure 4(a) Effect of MLF on serum TC level in rats (mmol/L, ). (b) Effects of MLF on serum TG level in rats (mmol/L, ). (c) Effects of MLF on serum HDL-C level in rats (mmol/L, ). (d) Effects of MLF on serum LDL-C level in rats (mmol/L, ).
Figure 5Effect of MLF on pathological sections of rat liver. (a) Control group. (b) T2DM group. (c) Metformin group. (d) HMLF group. (e) MMLF group. (f) LMLF group.
Figure 6(a) The effect of MLF on serum IL-1β level in rats (pg/ml, ). (b) The effect of MLF on serum IL-6 level in rats (pg/ml, ). (c) The effect of MLF on serum TNF-α level in rats (pg/ml, ).
Figure 7Effect of MLF on protein expression of TLR4/MyD88/NF-κB signaling pathway.